AIM ImmunoTech presented positive Ampligen trial data for pancreatic cancer at the MSCI Symposium, highlighting Progression-Free and Overall Survival.
Quiver AI Summary
AIM ImmunoTech Inc. showcased the progress of its lead drug Ampligen for pancreatic cancer treatment at the 5th Annual Marie Skłodowska-Curie Symposium, detailing promising data on Progression-Free Survival and Overall Survival from the DURIPANC clinical trial and an Early Access Program. CEO Thomas K. Equels discussed the significance of Ampligen in treating advanced pancreatic cancer, highlighting its potential for improving patient outcomes in a field with high unmet needs. The ongoing Phase 2 DURIPANC study is testing Ampligen in combination with AstraZeneca's durvalumab. AIM holds patent protection for this therapy in the US until 2039 and has received orphan drug designations in both the US and EU. The presentation slides are available on the company's website, where further information can also be found.
Potential Positives
- Ampligen demonstrated promising results in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and the Early Access Program, indicating potential effectiveness in treating pancreatic cancer.
- The presentation at the prestigious International 5th Annual Marie Skłodowska-Curie Symposium highlights the company's commitment to sharing significant advancements with the global medical community.
- AIM ImmunoTech's Ampligen has patent protection in the U.S. through 2039, providing potential market exclusivity for its combination therapy with durvalumab, enhancing its commercial outlook.
- The company’s ongoing Phase 2 DURIPANC clinical study evaluates a combination therapy with a well-known anti-PD-L1 inhibitor, which may increase its likelihood of regulatory approval.
Potential Negatives
- The press release emphasizes the unproven nature of Ampligen as a therapy for pancreatic cancer, stating that "data...do not guarantee that Ampligen will be approved as a therapy in pancreatic cancer."
- Despite positive progress, the release acknowledges significant risks and uncertainties associated with clinical success, which may deter investor confidence.
- There is a cautious tone regarding the dependence on future outcomes, as indicated by the repeated emphasis on "forward-looking statements" and the potential for numerous risk factors that could affect development and approval.
FAQ
What is Ampligen's role in pancreatic cancer treatment?
Ampligen is being investigated as a potential treatment for late-stage metastatic and locally advanced pancreatic cancer.
Where was the latest progress on Ampligen presented?
The latest progress was presented at the 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care in Warsaw, Poland.
What clinical trials are underway for Ampligen?
AIM ImmunoTech is conducting the Phase 2 DURIPANC clinical trial and an Early Access Program for Ampligen in pancreatic cancer.
What promising results have been observed with Ampligen?
Ampligen has shown positive data in Progression-Free Survival and Overall Survival in clinical trials.
How can I find more information about Ampligen?
More information can be found on AIM ImmunoTech's website at aimimmuno.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AIM Insider Trading Activity
$AIM insiders have traded $AIM stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AIM stock by insiders over the last 6 months:
- THOMAS K EQUELS (CEO & President) has made 4 purchases buying 2,009,714 shares for an estimated $54,302 and 0 sales.
- TED D KELLNER purchased 1,968,504 shares for an estimated $50,000
- WILLIAM M MITCHELL purchased 196,851 shares for an estimated $5,000
- PETER W III RODINO (COO, Secretary, Gen. Counsel) purchased 500 shares for an estimated $43
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AIM Hedge Fund Activity
We have seen 0 institutional investors add shares of $AIM stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 2,444,319 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $21,143,359
- BLACKROCK, INC. removed 698,267 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,040,009
- GEODE CAPITAL MANAGEMENT, LLC removed 531,334 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,596,039
- RENAISSANCE TECHNOLOGIES LLC removed 317,979 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,750,518
- STATE STREET CORP removed 173,103 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,497,340
- VERITION FUND MANAGEMENT LLC removed 162,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,401,300
- NORTHERN TRUST CORP removed 85,119 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $736,279
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5 th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here
Ampligen has demonstrated data-driven promise in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and an Early Access Program
OCALA, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the presentation on the latest positive progress from its Ampligen clinical program in pancreatic cancer at the 5 th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care hosted by and at Poland’s National Institute of Oncology in Warsaw, Poland.
AIM CEO Thomas K. Equels provided an overview of data from AIM’s pancreatic cancer Early Access Program and the latest advancements in the Phase 2 DURIPANC pancreatic cancer clinical trial currently underway at Erasmus University Medical Center in the Netherlands. The slides accompanying the presentation are now available on the Company’s website .
“Ampligen continues to demonstrate its potential for the treatment of late-stage metastatic and locally advanced pancreatic cancer. Our growing body of positive data continues to bolster our confidence. This lethal malignancy is a high unmet need. In particular, the Progression-Free Survival and Overall Survival – which are the gold standards for drug approval – seen in the clinical data demonstrated to date underscore our strong belief in the potential,” AIM ImmunoTech CEO Thomas K. Equels stated. “I am pleased to be a part of this gathering of global regulatory leaders, world-renowned oncologists and biopharma industry to share this important progress with Ampligen and highlight its potential in late-stage pancreatic cancer. We look forward to advancing its development and remain committed to bringing it to patients in desperate need and without real hope.”
AIM’s drug Ampligen is currently being tested in an ongoing Phase 2 DURIPANC clinical study evaluating the combination therapy of Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor durvalumab in the treatment of late-stage metastatic pancreatic cancer patients (See: ClinicalTrials.gov NCT05927142 ). Ampligen has patent protection for such a combination therapy in the United States through 2039, and US and EU orphan drug designations that will grant market protections for an approved drug.
For more information on Ampligen and to stay up to date with the latest advancements, please visit the Company’s website, aimimmuno.com .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen
®
(rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit
aimimmuno.com
and connect with the Company on
X
,
LinkedIn
, and
Facebook
.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5084607c-f35a-48da-8b06-10fa35de54ff
